DalsnaFinance Account

AstraZeneca $AZN

Healthcare · Europe

Europe United Kingdom

Create a scorecard

12,618.00p

+218.00 (+1.76%)

As of Oct 20, 2026, 3:26 PM EDT

Price history

Loading chart…

AstraZeneca (AZN) is trading up at 12,618.00p (+1.76%) on Europe, as of the latest quote. It is a Europe constituent in the Healthcare sector.

AstraZeneca revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)

AstraZeneca annual financial statements
	FY2016Dec 2016	FY2017Dec 2017	FY2018Dec 2018	FY2019Dec 2019	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$23.0B	$22.5B	$22.1B	$24.4B	$26.6B	$37.4B	$44.4B	$45.8B	$54.1B	$58.7B
Growth (year over year)	−6.9%	−2.3%	−1.7%	+10.4%	+9.2%	+40.6%	+18.5%	+3.3%	+18.0%	+8.6%
Gross profit	$18.9B	$18.1B	$17.2B	$19.5B	$21.3B	$25.0B	$32.0B	$37.5B	$43.9B	$48.1B
Gross margin	82.1%	80.8%	77.7%	79.8%	80.1%	66.8%	72.1%	82.0%	81.1%	81.9%
Operating income	$4.90B	$3.68B	$3.39B	$2.92B	$5.16B	$1.06B	$3.76B	$8.19B	$10.0B	$13.7B
Operating margin	21.3%	16.4%	15.3%	12.0%	19.4%	2.8%	8.5%	17.9%	18.5%	23.4%
Net income	$3.50B	$3.00B	$2.15B	$1.33B	$3.20B	$112.0M	$3.29B	$5.96B	$7.04B	$10.2B
Net margin	15.2%	13.4%	9.8%	5.5%	12.0%	0.3%	7.4%	13.0%	13.0%	17.4%
EPS (diluted)	$2.76	$2.37	$1.70	$1.03	$2.44	$0.08	$2.11	$3.81	$4.50	$6.54
Balance sheet
Cash and equivalents	$5.02B	$3.32B	$4.83B	$5.37B	$7.83B	$6.33B	$6.17B	$5.84B	$5.49B	$5.71B
Total assets	$62.5B	$63.4B	$60.7B	$61.4B	$66.7B	$105.4B	$96.5B	$101.1B	$104.0B	$114.1B
Total liabilities	$45.9B	$46.7B	$46.6B	$46.8B	$51.1B	$66.1B	$59.4B	$62.0B	$63.2B	$65.4B
Shareholders' equity	$14.9B	$15.0B	$12.5B	$13.1B	$15.6B	$39.3B	$37.0B	$39.1B	$40.8B	$48.7B
Cash flow
Operating cash flow	$4.14B	$3.58B	$2.62B	$2.97B	$4.80B	$5.96B	$9.81B	$10.3B	$11.9B	$14.6B
Capital expenditure	$1.45B	$1.33B	$1.04B	$979.0M	$961.0M	$1.09B	$1.09B	$1.36B	$1.92B	$2.81B
Free cash flow	$2.70B	$2.25B	$1.57B	$1.99B	$3.84B	$4.87B	$8.72B	$8.98B	$9.94B	$11.8B
Dividends paid	$3.56B	$3.52B	$3.48B	$3.59B	$3.57B	$3.86B	$4.36B	$4.48B	$4.63B	$4.97B
Share buybacks	—	—	—	—	—	$149.0M	—	—	$81.0M	$521.0M

RevenueNet incomeNet margin (right axis, %)

AstraZeneca quarterly financial statements
	Q2 FY23Jun 2023	Q4 FY23Dec 2023	Q1 FY24^†Mar 2024	Q2 FY24Jun 2024	Q4 FY24Dec 2024	Q1 FY25^†Mar 2025	Q2 FY25Jun 2025	Q4 FY25Dec 2025
Income statement
Revenue	$11.4B	—	$12.7B	$12.9B	—	$13.6B	$14.5B	—
Growth (year over year)	+6.0%	—	+16.5%	+13.3%	—	+7.2%	+11.7%	—
Gross profit	$9.46B	—	$10.5B	$10.8B	—	$11.3B	$12.0B	—
Gross margin	82.8%	—	82.5%	83.1%	—	83.5%	82.9%	—
Operating income	$2.46B	—	$3.12B	$2.75B	—	$3.67B	$3.51B	—
Operating margin	21.5%	—	24.6%	21.2%	—	27.0%	24.3%	—
Net income	$1.82B	—	$2.18B	$1.93B	—	$2.92B	$2.45B	—
Net margin	15.9%	—	17.2%	14.9%	—	21.5%	16.9%	—
EPS (diluted)	$1.17	—	$1.39	$1.24	—	$1.87	$1.57	—
Balance sheet
Cash and equivalents	$5.66B	$5.84B	—	$6.92B	$5.49B	—	$7.06B	$5.71B
Total assets	$96.5B	$101.1B	—	$104.3B	$104.0B	—	$112.4B	$114.1B
Total liabilities	$59.1B	$62.0B	—	$64.7B	$63.2B	—	$67.6B	$65.4B
Shareholders' equity	$37.4B	$39.1B	—	$39.5B	$40.8B	—	$44.7B	$48.7B

From AstraZeneca's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About AstraZeneca

AstraZeneca plc (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

Source: Wikipedia — AstraZeneca